Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Kim, Seung Up ^a,b   Lee, Ji Hoon ^a   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b,c   Jung, Kyu Sik ^a   Choi, Eun Hee ^a   Park, Young Nyun ^a,c   Han, Kwang Hyub ^a,b,c   Chon, Chae Yoon ^a,b   Park, Jun Yong ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT;

ADD ON THERAPY; ADULT; ADVANCED LIVER FIBROSIS; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER EXAMINATION; LIVER FIBROSIS; LIVER RELATED EVENT; MALE; PREDICTOR VARIABLE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VIRUS LOAD; DRUG EFFECT; ECHOGRAPHY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; VIROLOGY;

BACTERIA (MICROORGANISMS); HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; VIRAL LOAD;

EID: 84860523129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036676     Document Type: Article

References (46)

1. Margolis HS, Alter MJ, Hadler SC, (1991) Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 11: 84-92.
2. WHO, (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6: 35-47.
3. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, et al. (1999) The long-term course of chronic hepatitis B. Hepatology 30: 257-264.
4. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, et al. (1998) Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatology 28: 930-938.
5. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, Tommasini M, et al. (1991) Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325: 675-680.
6. Tanaka R, Itoshima T, Nagashima H, (1987) Follow-up study of 582 liver cirrhosis patients for 26 years in Japan. Liver 7: 316-324.
7. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, et al. (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21: 77-82.
8. Bravo AA, Sheth SG, Chopra S, (2001) Liver biopsy. N Engl J Med 344: 495-500.
9. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.
10. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bali B, et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408.
11. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, et al. (2006) Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 44: 1511-1517.
12. Kazemi F, Kettaneh A, N'Kontchou G, Pinto E, Ganne-Carrie N, et al. (2006) Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatology 45: 230-235.
13. Kim BK, Han KH, Park JY, Ahn SH, Kim JK, et al. (2010) A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterology 105: 1382-1390.
14. Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, et al. (2011) Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 53: 885-894.
15. Kim HS, Kim JK, Park YN, Nyung SM, Pang MS, et al. (2007) Non-invasive assessment of liver fibrosis by measuring the liver stiffness and biochemical markers in chronic hepatitis B patients. Korean J Med 72: 459-469.
16. Masuzaki R, Tateishi R, Yoshida H, Yoshida H, Sato S, et al. (2008) Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol 42: 839-843.
17. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, et al. (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29: 1705-1713.
18. Batts KP, Ludwig J, (1995) Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19: 1409-1417.
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR, (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterology 94: 2467-2474.
20. Patch D, Dagher L, (2001) Acute variceal bleeding: general management. World J Gastroenterol 7: 466-475.
21. Moore KP, Aithal GP, (2006) Guidelines on the management of ascites in cirrhosis. Gut 55 (Suppl 6): vi1-12.
22. Prakash R, Mullen KD, (2010) Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 7: 515-525.
23. Such J, Runyon BA, (1998) Spontaneous bacterial peritonitis. Clin Infect Dis 27:669-674; quiz 675-6.
24. Gines P, Arroyo V, (1999) Hepatorenal syndrome. J Am Soc Nephrol 10: 1833-1839.
25. Bruix J, Sherman M, (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
26. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, et al. (2011) On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antiviral ther 16: 165-172.
27. Min AD, Dienstag JL, (2007) Oral antivirals for chronic hepatitis B. Clin Liver Dis 11:851-868, ix.
28. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF, (1999) Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29: 971-975.
29. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, et al. (1986) Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90: 263-267.
30. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, et al. (1994) Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 74: 2234-2238.
31. Oon CJ, (1992) Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 31 Suppl pp. S137-142.
32. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, et al. (2002) Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterology 97: 2886-2895.
33. Liaw YF, Lin DY, Chen TJ, Chu CM, (1989) Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 9: 235-241.
34. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, et al. (1999) Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 116: 378-386.
35. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, et al. (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24: 141-147.
36. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, et al. (1999) Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30: 743-748.
37. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A, (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53: 348-356.
38. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Eng J Med 351: 1521-1531.
39. Fung SK, Lok AS, (2005) Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol 42 Suppl pp. S54-64.
40. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, et al. (2003) Histological outcome during long-term lamivudine therapy. Gastroenterology 124: 105-117.
41. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
42. Zakareya T, Razek WA, Allam N, Gabal AA, Rewisha E, et al. (2010) The utility of transient elastography in predicting complications of chronic liver disease. Nile Liver J 1: 49-57.
43. Kim do Y, Kim SU, Ahn SH, Park JY, Lee JM, et al. (2009) Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci 54: 1758-1763.
44. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, et al. (2009) Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 29: 242-247.
45. Kim SU, Kim JK, Park YN, Han KH, (2012) Discordance between liver biopsy and FibroScan® in assessing liver fibrosis in chronic hepatitis B: Risk factors and influence of necroinflammation. PLoS One 7: e322233.
46. Kim SU, Park JY, Kim do Y, Ahn SH, Kim HM, et al. (2010) Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int 4: 673-680.